NeoGenomics reported third-quarter 2026 revenue of $209 million, up 11% from a year earlier, and a GAAP net loss of $8 million, down from $27 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and narrowed its net loss outlook, and it said CEO Tony Zook will move to Executive Chairman as Warren Stone becomes CEO on January 4, 2027.
Q3 2026 revenue was $209 million, up 11%; clinical revenue was $195 million, up 13%, with NGS revenue up 29%.
Q3 2026 GAAP net loss was $8 million, compared with $27 million in Q3 2025; adjusted EBITDA was $19 million, up 53%.
Updated FY 2026 revenue guidance is $807 million to $809 million, up from $802 million to $806 million; adjusted EBITDA guidance is approximately $60 million, up from $56 million to $58 million.
Warren Stone, currently President and COO, will become CEO and a Board member effective January 4, 2027.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.